FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1520-1528 November 23, 2000 Number 21 Next

	Full Text PDF Supplementary Disclosure Editorial by Curfman, G. D. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Each year, clinical upper gastrointestinal events occur in 2 to 4 percent of patients who are taking nonselective nonsteroidal antiinflammatory drugs (NSAIDs). We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID naproxen among patients with rheumatoid arthritis.

Methods We randomly assigned 8076 patients who were at least 50 years of age (or at least 40 years of age and receiving long-term glucocorticoid therapy) and who had rheumatoid arthritis to receive either 50 mg of rofecoxib daily or 500 mg of naproxen twice daily. The primary end point was confirmed clinical upper gastrointestinal events (gastroduodenal perforation or obstruction, upper gastrointestinal bleeding, and symptomatic gastroduodenal ulcers).

Results Rofecoxib and naproxen had similar efficacy against rheumatoid arthritis. During a median follow-up of 9.0 months, 2.1 confirmed gastrointestinal events per 100 patient-years occurred with rofecoxib, as compared with 4.5 per 100 patient-years with naproxen (relative risk, 0.5; 95 percent confidence interval, 0.3 to 0.6; P<0.001). The respective rates of complicated confirmed events (perforation, obstruction, and severe upper gastrointestinal bleeding) were 0.6 per 100 patient-years and 1.4 per 100 patient-years (relative risk, 0.4; 95 percent confidence interval, 0.2 to 0.8; P=0.005). The incidence of myocardial infarction was lower among patients in the naproxen group than among those in the rofecoxib group (0.1 percent vs. 0.4 percent; relative risk, 0.2; 95 percent confidence interval, 0.1 to 0.7); the overall mortality rate and the rate of death from cardiovascular causes were similar in the two groups.

Conclusions In patients with rheumatoid arthritis, treatment with rofecoxib, a selective inhibitor of cyclooxygenase-2, is associated with significantly fewer clinically important upper gastrointestinal events than treatment with naproxen, a nonselective inhibitor.

Source Information

From the Institute for Work and Health, Mount Sinai Hospital, and the University Health Network, Toronto (C.B.); the Gastrointestinal Division, Department of Medicine, University of Southern California School of Medicine, Los Angeles (L.L.); Merck, Rahway, N.J. (A.R., D.S.); the Faculty of Medicine and Research Division, Universidad Nacional Autonoma de Mexico, and Hospital General de Mexico, Mexico City, Mexico (R.B.-V.); University of Texas–Houston School of Public Health, Houston (B.D.); the Department of Clinical Pharmacology, University of New South Wales and St. Vincent's Hospital, Sydney, Australia (R.D.); the Division of Rheumatology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil (M.B.F.); the Division of Gastroenterology, School of Medical and Surgical Sciences, University Hospital, Nottingham, United Kingdom (C.J.H.); the Division of Rheumatology and Clinical Immunology, University of Maryland, Baltimore (M.C.H.); Oslo City Department of Rheumatology, and Diakonhjemmet Hospital, Oslo, Norway (T.K.K.); and the Office of Clinical Research and Training, Northwestern University School of Medicine, Chicago (T.J.S.). Arthur Weaver, M.D., Arthritis Center of Nebraska, Lincoln, was another author.

Address reprint requests to Dr. Bombardier at the Institute for Work and Health, 250 Bloor St. E., Suite 702, Toronto, ON M4W 1E6, Canada, or at claire.bombardier{at}utoronto.ca.

Full Text of this Article

This article has been cited by other articles:

• Solomon, S. D., Wittes, J., Finn, P. V., Fowler, R., Viner, J., Bertagnolli, M. M., Arber, N., Levin, B., Meinert, C. L., Martin, B., Pater, J. L., Goss, P. E., Lance, P., Obara, S., Chew, E. Y., Kim, J., Arndt, G., Hawk, E., for the Cross Trial Safety Assessment Group, (2008). Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: The Cross Trial Safety Analysis. Circulation 117: 2104-2113 [Abstract] [Full Text]  
• Ross, J. S., Hill, K. P., Egilman, D. S., Krumholz, H. M. (2008). Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib Litigation. JAMA 299: 1800-1812 [Abstract] [Full Text]  
• Ferrario, C. M. (2008). Editorial: On the selective inhibitors of Cyclooxygenase-2: Do we have a last word?. Therapeutic Advances in Cardiovascular Disease 2: 75-78  
• Fidler, M. J., Argiris, A., Patel, J. D., Johnson, D. H., Sandler, A., Villaflor, V. M., Coon, J. IV, Buckingham, L., Kaiser, K., Basu, S., Bonomi, P. (2008). The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non-Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib. Clin. Cancer Res. 14: 2088-2094 [Abstract] [Full Text]  
• van Staa, T P, Smeeth, L, Persson, I, Parkinson, J, Leufkens, H G M (2008). What is the harm-benefit ratio of Cox-2 inhibitors?. Int J Epidemiol 37: 405-413 [Abstract] [Full Text]  
• Degousee, N., Fazel, S., Angoulvant, D., Stefanski, E., Pawelzik, S.-C., Korotkova, M., Arab, S., Liu, P., Lindsay, T. F., Zhuo, S., Butany, J., Li, R.-K., Audoly, L., Schmidt, R., Angioni, C., Geisslinger, G., Jakobsson, P.-J., Rubin, B. B. (2008). Microsomal Prostaglandin E2 Synthase-1 Deletion Leads to Adverse Left Ventricular Remodeling After Myocardial Infarction. Circulation 117: 1701-1710 [Abstract] [Full Text]  
• Hennekens, C. H., Borzak, S. (2008). Cyclooxygenase-2 Inhibitors and Most Traditional Nonsteroidal Anti-inflammatory Drugs Cause Similar Moderately Increased Risks of Cardiovascular Disease. J CARDIOVASC PHARMACOL THER 13: 41-50 [Abstract]  
• Krueger, K, Lino, L, Dore, R, Radominski, S, Zhang, Y, Kaur, A, Simpson, R, Curtis, S (2008). Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). Ann Rheum Dis 67: 315-322 [Abstract] [Full Text]  
• Underwood, M., Ashby, D., Cross, P., Hennessy, E., Letley, L., Martin, J., Mt-Isa, S., Parsons, S., Vickers, M., Whyte, K., on behalf of the TOIB study team, (2008). Advice to use topical or oral ibuprofen for chronic knee pain in older people: randomised controlled trial and patient preference study. BMJ 336: 138-142 [Abstract] [Full Text]  
• Frolov, R. V., Berim, I. G., Singh, S. (2008). Inhibition of Delayed Rectifier Potassium Channels and Induction of Arrhythmia: A NOVEL EFFECT OF CELECOXIB AND THE MECHANISM UNDERLYING IT. J. Biol. Chem. 283: 1518-1524 [Abstract] [Full Text]  
• Deeb, R. S., Upmacis, R. K., Lamon, B. D., Gross, S. S., Hajjar, D. P. (2008). Maintaining Equilibrium by Selective Targeting of Cyclooxygenase Pathways: Promising Offensives Against Vascular Injury. Hypertension 51: 1-7 [Full Text]  
• Joshi, G. P., Gertler, R., Fricker, R. (2007). Cardiovascular Thromboembolic Adverse Effects Associated with Cyclooxygenase-2 Selective Inhibitors and Nonselective Antiinflammatory Drugs. Anesth. Analg. 105: 1793-1804 [Abstract] [Full Text]  
• Kellogg, A. P., Wiggin, T. D., Larkin, D. D., Hayes, J. M., Stevens, M. J., Pop-Busui, R. (2007). Protective Effects of Cyclooxygenase-2 Gene Inactivation Against Peripheral Nerve Dysfunction and Intraepidermal Nerve Fiber Loss in Experimental Diabetes. Diabetes 56: 2997-3005 [Abstract] [Full Text]  
• Hoes, J N, Jacobs, J W G, Boers, M, Boumpas, D, Buttgereit, F, Caeyers, N, Choy, E H, Cutolo, M, Da Silva, J A P, Esselens, G, Guillevin, L, Hafstrom, I, Kirwan, J R, Rovensky, J, Russell, A, Saag, K G, Svensson, B, Westhovens, R, Zeidler, H, Bijlsma, J W J (2007). EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 66: 1560-1567 [Abstract] [Full Text]  
• Letts, G., Loscalzo, J. (2007). Frontiers in Nephrology: Targeting Inflammation Using Novel Nitric Oxide Donors. J. Am. Soc. Nephrol. 18: 2863-2869 [Abstract] [Full Text]  
• Scott, P A, Kingsley, G H, Smith, C M, Choy, E H, Scott, D L (2007). Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis 66: 1296-1304 [Abstract] [Full Text]  
• Glasser, S. P., Salas, M., Delzell, E. (2007). Importance and Challenges of Studying Marketed Drugs: What Is a Phase IV Study? Common Clinical Research Designs, Registries, and Self-Reporting Systems. J Clin Pharmacol 47: 1074-1086 [Abstract] [Full Text]  
• Gray, J., Mao, J. T., Szabo, E., Kelley, M., Kurie, J., Bepler, G. (2007). Lung Cancer Chemoprevention: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition). Chest 132: 56S-68S [Abstract] [Full Text]  
• Delaney, J. A. MSc, Opatrny, L. MD MSc, Brophy, J. M. MD PhD, Suissa, S. PhD (2007). Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 177: 347-351 [Abstract] [Full Text]  
• O'Byrne, K. J., Danson, S., Dunlop, D., Botwood, N., Taguchi, F., Carbone, D., Ranson, M. (2007). Combination Therapy With Gefitinib and Rofecoxib in Patients With Platinum-Pretreated Relapsed Non Small-Cell Lung Cancer. JCO 25: 3266-3273 [Abstract] [Full Text]  
• Timmers, L., Pasterkamp, G., de Kleijn, D. P.V. (2007). Microsomal Prostaglandin E2 Synthase: A Safer Target than Cyclooxygenases?. Mol. Interv. 7: 195-199 [Abstract] [Full Text]  
• Smith, R. (2007). Should medical journals carry drug advertising? Yes. BMJ 335: 74-74 [Full Text]  
• Reuben, S. S., Ekman, E. F., Charron, D. (2007). Evaluating the Analgesic Efficacy of Administering Celecoxib as a Component of Multimodal Analgesia for Outpatient Anterior Cruciate Ligament Reconstruction Surgery. Anesth. Analg. 105: 222-227 [Abstract] [Full Text]  
• Waksman, J. C, Brody, A., Phillips, S. D (2007). Nonselective Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk: Are They Safe?. The Annals of Pharmacotherapy 41: 1163-1173 [Abstract] [Full Text]  
• Reginster, J Y, Malmstrom, K, Mehta, A, Bergman, G, Ko, A T, Curtis, S P, Reicin, A S (2007). Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis 66: 945-951 [Abstract] [Full Text]  
• Reuben, S. S., Buvanendran, A. (2007). Preventing the Development of Chronic Pain After Orthopaedic Surgery with Preventive Multimodal Analgesic Techniques. JBJS 89: 1343-1358 [Abstract] [Full Text]  
• Wang, J., Mullins, C D., Mamdani, M., Rublee, D. A, Shaya, F. T (2007). New Diagnosis of Hypertension Among Celecoxib and Nonselective NSAID Users: A Population-Based Cohort Study. The Annals of Pharmacotherapy 41: 937-943 [Abstract] [Full Text]  
• Farkouh, M E, Greenberg, J D, Jeger, R V, Ramanathan, K, Verheugt, F W A, Chesebro, J H, Kirshner, H, Hochman, J S, Lay, C L, Ruland, S, Mellein, B, Matchaba, P T, Fuster, V, Abramson, S B (2007). Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis 66: 764-770 [Abstract] [Full Text]  
• Brune, K., Furst, D. E. (2007). Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability?. Rheumatology (Oxford) 46: 911-919 [Abstract] [Full Text]  
• Criner, G. J. (2007). Framing the Forum: Medical Ethics in Large-Scale, Interventional Respiratory Clinical Trials. Proc Am Thorac Soc 4: 171-175 [Abstract] [Full Text]  
• Schwartz, J. I., Agrawal, N. G. B., Hartford, A. H., Cote, J., Hunt, T. L., Verbesselt, R., Eckols, D. R., Gottesdiener, K. M. (2007). The Effect of Etoricoxib on the Pharmacodynamics and Pharmacokinetics of Warfarin. J Clin Pharmacol 47: 620-627 [Abstract] [Full Text]  
• Rostom, A., Dube, C., Lewin, G., Tsertsvadze, A., Barrowman, N., Code, C., Sampson, M., Moher, D. (2007). Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review Prepared for the U.S. Preventive Services Task Force. ANN INTERN MED 146: 376-389 [Abstract] [Full Text]  
• Ong, C.K.S., Lirk, P., Tan, C.H., Seymour, R.A. (2007). An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs. Clin Med Res 5: 19-34 [Abstract] [Full Text]  
• Kesselheim, A. S., Mello, M. M. (2007). Confidentiality Laws And Secrecy In Medical Research: Improving Public Access To Data On Drug Safety. Health Aff (Millwood) 26: 483-491 [Abstract] [Full Text]  
• Himmelfarb, J. (2007). Continuous Renal Replacement Therapy in the Treatment of Acute Renal Failure: Critical Assessment Is Required. CJASN 2: 385-389 [Abstract] [Full Text]  
• Zhang, W, Doherty, M, Leeb, B F, Alekseeva, L, Arden, N K, Bijlsma, J W, Dincer, F, Dziedzic, K, Hauselmann, H J, Herrero-Beaumont, G, Kaklamanis, P, Lohmander, S, Maheu, E, Martin-Mola, E, Pavelka, K, Punzi, L, Reiter, S, Sautner, J, Smolen, J, Verbruggen, G, Zimmermann-Gorska, I (2007). EULAR evidence based recommendations for the management of hand osteoarthritis: Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66: 377-388 [Abstract] [Full Text]  
• Bingham, C. O. III, Sebba, A. I., Rubin, B. R., Ruoff, G. E., Kremer, J., Bird, S., Smugar, S. S., Fitzgerald, B. J., O'Brien, K., Tershakovec, A. M. (2007). Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford) 46: 496-507 [Abstract] [Full Text]  
• Rahme, E., Nedjar, H. (2007). Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology (Oxford) 46: 435-438 [Abstract] [Full Text]  
• White, W. B. (2007). Cardiovascular Effects of the Cyclooxygenase Inhibitors. Hypertension 49: 408-418 [Full Text]  
• Kapoor, M., Kojima, F., Qian, M., Yang, L., Crofford, L. J. (2007). Microsomal Prostaglandin E Synthase-1 Deficiency Is Associated with Elevated Peroxisome Proliferator-activated Receptor {gamma}: REGULATION BY PROSTAGLANDIN E2 VIA THE PHOSPHATIDYLINOSITOL 3-KINASE AND AKT PATHWAY. J. Biol. Chem. 282: 5356-5366 [Abstract] [Full Text]  
• Hix, M. D. (2007). Pain Management in Elderly Patients. Journal of Pharmacy Practice 20: 49-63 [Abstract]  
• Brophy, J M, Levesque, L E, Zhang, B (2007). The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart 93: 189-194 [Abstract] [Full Text]  
• Binymin, K. A., Phillips, K. (2007). "To do no harm". Rheumatology (Oxford) 46: 368-370 [Full Text]  
• Timmers, L., Sluijter, J. P.G., Verlaan, C. W.J., Steendijk, P., Cramer, M. J., Emons, M., Strijder, C., Grundeman, P. F., Sze, S. K., Hua, L., Piek, J. J., Borst, C., Pasterkamp, G., de Kleijn, D. P.V. (2007). Cyclooxygenase-2 Inhibition Increases Mortality, Enhances Left Ventricular Remodeling, and Impairs Systolic Function After Myocardial Infarction in the Pig. Circulation 115: 326-332 [Abstract] [Full Text]  
• Zarraga, I. G. E., Schwarz, E. R. (2007). Coxibs and Heart Disease: What We Have Learned and What Else We Need to Know. J Am Coll Cardiol 49: 1-14 [Abstract] [Full Text]  
• Vidal, C., Gomez-Hernandez, A., Sanchez-Galan, E., Gonzalez, A., Ortega, L., Gomez-Gerique, J. A., Tunon, J., Egido, J. (2007). Licofelone, a Balanced Inhibitor of Cyclooxygenase and 5-Lipoxygenase, Reduces Inflammation in a Rabbit Model of Atherosclerosis. J. Pharmacol. Exp. Ther. 320: 108-116 [Abstract] [Full Text]  
• Yazici, Y, Yazici, H (2007). A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor {alpha} inhibitors. Ann Rheum Dis 66: 124-127 [Abstract] [Full Text]  
• Gaffo, A., Saag, K. G., Curtis, J. R. (2006). Treatment of rheumatoid arthritis. Am J Health Syst Pharm 63: 2451-2465 [Abstract] [Full Text]  
• Mamdani, M., Warren, L., Kopp, A., Paterson, J. M., Laupacis, A., Bassett, K., Anderson, G. M. (2006). Changes in rates of upper gastrointestinal hemorrhage after the introduction of cyclooxygenase-2 inhibitors in British Columbia and Ontario. CMAJ 175: 1535-1538 [Abstract] [Full Text]  
• Mitchell, J. A., Lucas, R., Vojnovic, I., Hasan, K., Pepper, J. R., Warner, T. D. (2006). Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB J. 20: 2468-2475 [Abstract] [Full Text]  
• Lanas, A, Garcia-Rodriguez, L A, Arroyo, M T, Gomollon, F, Feu, F, Gonzalez-Perez, A, Zapata, E, Bastida, G, Rodrigo, L, Santolaria, S, Guell, M, de Argila, C M, Quintero, E, Borda, F, Pique, J M, on behalf of the Investigators of the Asociacion E, (2006). Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 55: 1731-1738 [Abstract] [Full Text]  
• Madhok, R., Wu, O., McKellar, G., Singh, G. (2006). Non-steroidal anti-inflammatory drugs--changes in prescribing may be warranted. Rheumatology (Oxford) 45: 1458-1460 [Full Text]  
• Bruce, I N (2006). The influence of other drugs on coronary heart disease (CHD) risk in systemic lupus erythematosus. Lupus 15: 23-26 [Abstract]  
• Schneider, V., Levesque, L. E., Zhang, B., Hutchinson, T., Brophy, J. M. (2006). Association of Selective and Conventional Nonsteroidal Antiinflammatory Drugs with Acute Renal Failure: A Population-based, Nested Case-Control Analysis. Am J Epidemiol 164: 881-889 [Abstract] [Full Text]  
• Buvanendran, A, Reuben, S S (2006). COX-2 inhibitors in sports medicine: utility and controversy. Br. J. Sports. Med. 40: 895-896 [Full Text]  
• Harris, C. L, Raisch, D. W, Abhyankar, U., Marfatia, S., Campbell, H. M, Sather, M. R (2006). GI Risk Factors and Use of GI Protective Agents Among Patients Receiving Nonsteroidal Antiinflammatory Drugs. The Annals of Pharmacotherapy 40: 1924-1931 [Abstract] [Full Text]  
• Graham, D. J. (2006). COX-2 Inhibitors, Other NSAIDs, and Cardiovascular Risk: The Seduction of Common Sense. JAMA 296: 1653-1656 [Full Text]  
• McGettigan, P., Henry, D. (2006). Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2. JAMA 296: 1633-1644 [Abstract] [Full Text]  
• Zhang, J., Ding, E. L., Song, Y. (2006). Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized Trials. JAMA 296: 1619-1632 [Abstract] [Full Text]  
• Chaiamnuay, S., Allison, J. J., Curtis, J. R. (2006). Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.. Am J Health Syst Pharm 63: 1837-1851 [Abstract] [Full Text]  
• Stafford-Smith, M. (2006). Hurry up and slow down: Lessons in drug development from the COX-2 inhibitors/Se hater et ralentir: les lecons a tirer de la production des inhibiteurs de la COX-2.. Canadian J. Anesthesia 53: 973-977 [Full Text]  
• Cheng, J. W. (2006). Use of Non-Aspirin Nonsteroidal Antiinflammatory Drugs and the Risk of Cardiovascular Events. The Annals of Pharmacotherapy 40: 1785-1796 [Abstract] [Full Text]  
• Wang, M., Zukas, A. M., Hui, Y., Ricciotti, E., Pure, E., FitzGerald, G. A. (2006). Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc. Natl. Acad. Sci. USA 103: 14507-14512 [Abstract] [Full Text]  
• Tanne, J. H. (2006). Reports cite cardiovascular risks of COX 2 inhibitors and NSAIDs. BMJ 333: 565-565 [Full Text]  
• Schmelzer, K. R., Inceoglu, B., Kubala, L., Kim, I.-H., Jinks, S. L., Eiserich, J. P., Hammock, B. D. (2006). Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc. Natl. Acad. Sci. USA 103: 13646-13651 [Abstract] [Full Text]  
• Solomon, S. D., Pfeffer, M. A., McMurray, J. J.V., Fowler, R., Finn, P., Levin, B., Eagle, C., Hawk, E., Lechuga, M., Zauber, A. G., Bertagnolli, M. M., Arber, N., Wittes, J., for the APC and PreSAP Trial Investigators, (2006). Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas. Circulation 114: 1028-1035 [Abstract] [Full Text]  
• Wang, H.-W., Hsueh, C.-T., Lin, C.-F. J., Chou, T.-Y., Hsu, W.-H., Wang, L.-S., Wu, Y.-C. (2006). Clinical Implications of Microsomal Prostaglandin E Synthase-1 Overexpression in Human Non-Small-Cell Lung Cancer. Ann. Surg. Oncol. 13: 1224-1234 [Abstract] [Full Text]  
• MICHAELS, D. (2006). Manufactured uncertainty: protecting public health in the age of contested science and product defense.. Ann. N. Y. Acad. Sci. 1076: 149-162 [Abstract] [Full Text]  
• de Leval, X., Dassesse, T., Dogne, J.-M., Waltregny, D., Bellahcene, A., Benoit, V., Pirotte, B., Castronovo, V. (2006). Evaluation of Original Dual Thromboxane A2 Modulators as Antiangiogenic Agents. J. Pharmacol. Exp. Ther. 318: 1057-1067 [Abstract] [Full Text]  
• DeAngelis, C. D. (2006). The Influence of Money on Medical Science. JAMA 296: 996-998 [Full Text]  
• Borgdorff, P., Tangelder, G. J., Paulus, W. J. (2006). Cyclooxygenase-2 Inhibitors Enhance Shear Stress-Induced Platelet Aggregation. J Am Coll Cardiol 48: 817-823 [Abstract] [Full Text]  
• Smith, R. (2006). Lapses at the new England journal of medicine.. JRSM 99: 380-382 [Full Text]  
• Rajakariar, R., Yaqoob, M. M., Gilroy, D. W. (2006). COX-2 in Inflammation and Resolution. Mol. Interv. 6: 199-207 [Abstract] [Full Text]  
• Oitate, M., Hirota, T., Koyama, K., Inoue, S.-i., Kawai, K., Ikeda, T. (2006). COVALENT BINDING OF RADIOACTIVITY FROM [14C]ROFECOXIB, BUT NOT [14C]CELECOXIB OR [14C]CS-706, TO THE ARTERIAL ELASTIN OF RATS. Drug Metab. Dispos. 34: 1417-1422 [Abstract] [Full Text]  
• Lippi, G, Franchini, M, Guidi, G C, Kean, W F (2006). Non-steroidal anti-inflammatory drugs in athletes * Commentary. Br. J. Sports. Med. 40: 661-663 [Full Text]  
• Qi, Z., Cai, H., Morrow, J. D., Breyer, M. D. (2006). Differentiation of Cyclooxygenase 1- and 2-Derived Prostanoids in Mouse Kidney and Aorta. Hypertension 48: 323-328 [Abstract] [Full Text]  
• Schneeweiss, S., Solomon, D. H. (2006). Not-so-surprising findings.. CMAJ 175: 171-172 [Full Text]  
• Kesselheim, A. S., Fischer, M. A., Avorn, J. (2006). The rise and fall of Natrecor for congestive heart failure: implications for drug policy.. Health Aff (Millwood) 25: 1095-1102 [Abstract] [Full Text]  
• Andersohn, F., Schade, R., Suissa, S., Garbe, E. (2006). Cyclooxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs and the Risk of Ischemic Stroke: A Nested Case-Control Study. Stroke 37: 1725-1730 [Abstract] [Full Text]  
• Rahme, E., Toubouti, Y., Hunsche, E. (2006). Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada. Rheumatology (Oxford) 45: 903-910 [Abstract] [Full Text]  
• Gislason, G. H., Jacobsen, S., Rasmussen, J. N., Rasmussen, S., Buch, P., Friberg, J., Schramm, T. K., Abildstrom, S. Z., Kober, L., Madsen, M., Torp-Pedersen, C. (2006). Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction. Circulation 113: 2906-2913 [Abstract] [Full Text]  
• Grosch, S., Maier, T. J., Schiffmann, S., Geisslinger, G. (2006). Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.. JNCI J Natl Cancer Inst 98: 736-747 [Abstract] [Full Text]  
• Kearney, P. M, Baigent, C., Godwin, J., Halls, H., Emberson, J. R, Patrono, C. (2006). Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.. BMJ 332: 1302-1308 [Abstract] [Full Text]  
• Dieppe, P. (2006). Complicity theory: an explanation for the ;coxib problem'?. JRSM 99: 273-274 [Full Text]  
• Weatherall, M., Aldington, S., Caldwell, B., Beasley, R. (2006). Inconsistencies in cardiovascular data from COX-2 inhibitor trials--is it a class effect?. JRSM 99: 275-276 [Full Text]  
• Smith, R. (2006). Conflicts of interest: how money clouds objectivity.. JRSM 99: 292-297 [Full Text]  
• Hur, C., Chan, A. T, Tramontano, A. C, Gazelle, G S. (2006). Coxibs Versus Combination NSAID and PPI Therapy for Chronic Pain: An Exploration of the Risks, Benefits, and Costs. The Annals of Pharmacotherapy 40: 1052-1063 [Abstract] [Full Text]  
• Pocock, S. J (2006). The simplest statistical test: how to check for a difference between treatments.. BMJ 332: 1256-1258 [Full Text]  
• Armstrong, P. W. (2006). Balancing the cyclooxygenase portfolio.. CMAJ 174: 1581-1582 [Full Text]